Coronavirus & Asthma, page-21

From Respiri (RSH) CEO Marjan Mikel’s last conference call:
”We are already in discussions with potential pharmaceutical partners to help us with the promotion of wheezo and the eHealth SaaS platform to respiratory physicians in Australia.”

Since this time we have learned that 4 - 5 of the largest pharmaceutical companies in the world have a strong reason to be interested in us - that is the development of asthma biologic drugs and the need to proof that patients require the stronger, more expensive drug because their existing medication plan is not working.

These Pharma companies who are focused on biologics include Astra Zeneca, Norvartis, GSK and a division of Roche.